Dr. Reddy's seeks DCGI nod to conduct phase-3 clinical trial of Russian COVID-19 vaccine Sputnik V

03 Oct 2020 Evaluate

Dr. Reddy's Laboratories has applied to the Drugs Controller General of India (DCGI) for permission to conduct phase-3 human clinical trials of the Russian vaccine Sputnik V against COVID-19 in India. The Indian pharma giant has collaborated with The Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V as well as its distribution.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1208.45 -15.85 (-1.29%)
29-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1589.30
Dr. Reddys Lab 1208.45
Cipla 1320.35
Zydus Lifesciences 890.20
Lupin 2131.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×